Monograph

A02BA03 - Famotidine

Propably not porphyrinogenic

Rationale

Partly unmetabolized. No clinical observations pointing to CYP inducing properties.

Chemical description

Used in peptic ulcer and gastro-oesophageal reflux (H2-receptor antagonist). About 70% excreted in urine in unmetabolized form. Partly metabolized in the liver to inactive sulfoxide metabolite. Impaired liver function does not seem to change the kinetics. South African list: use with care. French list: avoid Australian list: safe

IPNet drug reports

Uneventful use reported in 8 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes A02B / A02BA or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames